PD-RAD: A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer
Study Details
Study Description
Brief Summary
Participants with Non-Small Cell Lung Cancer (NSCLC), Performance Status (PS) 0-2, not suitable for concurrent Chemo-Radiotherapy (CTRT), will be treated with standard radiotherapy (radical or palliative). Archival tumour biopsies will be analysed for baseline Programmed Death Ligand 1 (PD-L1) expression. Some participants will have a biopsy before radiotherapy if the archive biopsy is not suitable. Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week of radiotherapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The purpose of this prospective, multicentre, non-randomised translational study is to provide proof of feasibility of achieving paired biopsies for PD-L1 assessment in patients with NSCLC treated with palliative or radical radiotherapy. This is a non-CTIMP study.
All participants will have a minimum of 1 mandatory biopsy (during radiotherapy [irradiated site]) and the potential to have a pre-treatment biopsy if archival biopsy does not meet the suitability criteria.
Participants will have up to a maximum of 2 additional optional biopsies (during radiotherapy [within the RT field e.g supraclavicular fossa node], [outside RT field e.g. skin met]).
Blood samples will also be taken on study at specified time points for immune monitoring (exploratory endpoints).
The study will be carried out in two stages as follows:
Stage 1:
Following the enrolment of the first 15 evaluable participants, an interim analysis will take place by the Trial Steering Committee (TSC). The TSC will make a recommendation on whether recruitment should continue to the Trial Management Group (TMG).
Stage 2:
A further 15 evaluable participants will be recruited onto the study to achieve a total of 30 evaluable participants.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Non-Small Cell Lung Cancer Participants with NSCLC not suitable for concurrent CTRT, being treated with standard radiotherapy (radical or palliative). All participants will be required to undergo a post radiotherapy course biopsy and will have blood samples taken. |
Procedure: Biopsy and blood samples
Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archival biopsy is not suitable.
Participants will be required to undergo an additional mandatory biopsy of the irradiated site during the second week. Patients must have completed at least 1 week of the planned treatment before taking the biopsy.
Participants will also be asked for consent to donate 50ml blood pre biopsy (at baseline and week 2) and at the end of radiotherapy; as well as 10ml blood before #2 radiotherapy and weekly throughout treatment.
|
Outcome Measures
Primary Outcome Measures
- Achieving paired biopsies for PD-L1 assessment in 21 of the 30 evaluable participants [Up to 6.5 weeks from start of radiotherapy]
Secondary Outcome Measures
- Suitability of pre and during radiotherapy biopsy for PD-L1 testing [Up to 6.5 weeks from start of radiotherapy]
Other Outcome Measures
- Change in PD-L1 expression level during treatment [Up to 6.5 weeks from start of radiotherapy]
- Difference in PD-L1 expression level in 'out of radiotherapy field' sites compared with irradiated sites [Up to 6.5 weeks from start of radiotherapy]
- Immune monitoring of primary tumour and peripheral blood mononuclear cells [Up to 6.5 weeks from start of radiotherapy]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed NSCLC
-
Diagnostic/pre-treatment biopsy suitable for PD-L1 analysis*
-
Tumour judged inoperable by a lung MDT
-
Tumour that is accessible to core biopsy
-
Age 18 and over, no upper age limit
-
Performance status (PS) - ECOG 0-2
-
Participant considered suitable for radiotherapy (palliative or radical) or sequential chemo-radiotherapy
-
Before participant registration, written informed consent must be given according to GCP and national regulations
-
Pre-treatment biopsy must be from gross tumour volume within planned radiation field, and must also:
-
have been formalin fixed for >12h and ≤24h
-
have tumour tissue and morphology confirmed by H&E staining
-
contain sufficient tumour cells (>100) to determine PD-L1 status
Exclusion Criteria:
-
Participant suitable for standard concurrent CTRT
-
Participant deemed unsuitable for repeat biopsies in the opinion of the treating oncologist
-
Participant known to have an EGFR mutation or an ALK rearrangement
-
Intercurrent or history of hepatitis B, C or human immunodeficiency virus infection, if known
-
Participants who have received more than 1 line of chemotherapy prior to radiotherapy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | St. James's Univerisity Hospital | Leeds | United Kingdom | LS9 7TF | |
| 2 | University College Hospital | London | United Kingdom | NW1 2BU | |
| 3 | The Christie NHS Foundation Trust | Manchester | United Kingdom | M20 4BX |
Sponsors and Collaborators
- The Christie NHS Foundation Trust
- AstraZeneca
Investigators
- Study Chair: Timothy Illidge, The Christie NHS Foundation Trust
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CFTSp095, 14_DOG07_183